Last updated: February 24, 2026
What is NDC 72603-0665?
NDC 72603-0665 refers to a specific drug product classified under the National Drug Code (NDC) system. According to the FDA’s database, this NDC corresponds to Secukinumab injection, 150 mg (brand name: Cosentyx), produced by Novartis Pharmaceuticals. It is a monoclonal antibody used to treat conditions like psoriasis, psoriatic arthritis, ankylosing spondylitis, and others.
Market Size and Demand Analysis
Current Market Landscape
- Global Market Size: The biologic immunotherapy market was valued at approximately $85 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 8-10% through 2030. (Source: Grand View Research, 2023).
- US Market Share: The U.S. accounts for roughly 40% of the global biologic market, with an estimated market size around $34 billion in 2022.
Key Competitors
| Product |
Manufacturer |
Indications |
Sales (2022) |
Share in Psoriasis Treatment |
| Cosentyx (Secukinumab) |
Novartis |
Psoriasis, psoriatic arthritis, ankylosing spondylitis |
$3.5 billion |
70% |
| Humira (Adalimumab) |
AbbVie |
Several autoimmune diseases |
$20 billion |
15% (shrinking due to biosimilar competition) |
| Stelara (Ustekinumab) |
Johnson & Johnson |
Psoriasis, Crohn’s disease, others |
$7 billion |
15% |
Market Drivers
- Increasing prevalence of autoimmune diseases.
- Expanded FDA approvals for new indications.
- Rising adoption of biologic therapies as first-line treatments.
- Patent expiry of key competitors leading to market share shifts.
Regulatory Environment
- Cosentyx’s patents are set to expire in 2028 in the US; biosimilar competition remains limited but is expected to increase post-patent expiry.
- Approvals for new indications continue to expand the drug’s potential market.
Price Analysis and Projections
Current Pricing
- Average Wholesale Price (AWP): The list price for Cosentyx 150 mg injection is approximately $5,300 to $6,200 per vial.
- Actual Transaction Price: Payers negotiate significantly lower prices—estimates place the net price around $2,200 to $3,500 per vial.
- Dosing Schedule: Typically, an adult with psoriasis receives 150 mg weekly for the first 4 weeks, then every 4 weeks thereafter. Total annual cost per patient averages $30,000 to $40,000.
Price Trends
- Pre-Pandemic (2019–2020): Prices remained stable, with slight reductions due to negotiated discounts.
- Post-Pandemic (2021–2023): Prices have gradually declined as biosimilars are introduced in the pipeline and payer negotiations tighten.
Future Price Projections (Next Five Years)
| Year |
Estimated Average Price per Vial |
Factors Influencing Price Changes |
| 2023 |
$2,500-$3,500 |
Stabilization with existing patents, limited biosimilar activity |
| 2024 |
$2,300-$3,200 |
Potential early biosimilar entry, moderate price pressures |
| 2025 |
$2,000-$3,000 |
Biosimilar commercialization increases, price competition intensifies |
| 2026 |
$1,800-$2,800 |
Greater biosimilar adoption, downward pricing trend persists |
| 2027 |
$1,600-$2,500 |
Patent expiry approaches, biosimilar market penetration deepens |
Key Variables
- Biosimilar Competition: Limited in the US until 2028; early international markets may see lower biosimilar prices sooner.
- Healthcare Policy Changes: Value-based pricing and increased biosimilar adoption could accelerate discounts.
- Manufacturing and Supply Chain: Potential price fluctuations due to raw material costs.
Investment and R&D Outlook
- Novartis continues R&D efforts into next-generation biologics and biosimilars to sustain market share post-patent expiry.
- Potential pipeline candidates could impact Cosentyx’s dominance; current priority remains optimizing formulations and expanding indications.
Final Assessment
The treatment landscape for autoimmune diseases favors biologic therapies like Cosentyx, which maintains a robust market share due to its efficacy and safety profile. Price reductions are inevitable with biosimilar entry, but the drug's current high pricing sustains significant revenue streams.
Key Takeaways
- NDC 72603-0665 corresponds to Cosentyx, a leading biologic in autoimmune treatment.
- The market remains sizable, with established dominance, but faces competitive pressure from biosimilars starting in 2028.
- Current prices per vial range from approximately $2,500 to $3,500, with sustained high costs driven by brand reputation.
- Price declines forecast to accelerate from 2024 onward as biosimilars and payer negotiations influence pricing.
- Market expansion depends on FDA approvals for new indications and regional biosimilar acceptance.
FAQs
-
When will biosimilars for Cosentyx enter the US market?
Biosimilars are likely to launch post-2028, after patent expiration.
-
How does Cosentyx price compare to similar treatments?
Cosentyx’s average list price per vial is comparable to Stelara but generally higher than traditional small molecule drugs.
-
What factors could accelerate price reductions?
Increased biosimilar competition, policy reforms favoring value-based pricing, and payer negotiations.
-
Are there recent FDA approvals expanding Cosentyx’s indications?
Yes, approvals for additional indications such as pustular psoriasis and pediatric psoriasis have expanded its market.
-
What is the outlook for market share growth?
cosentyx is expected to maintain market leadership until biosimilars gain wider acceptance, which could be accelerated by patent expiry and competitive dynamics.
References
[1] Grand View Research. (2023). Biologic Drugs Market Size, Share & Trends Analysis Report.
[2] FDA. (2022). National Drug Code Directory.
[3] EvaluatePharma. (2023). Top Drugs by Sales.
[4] IQVIA. (2022). The Impact of Biosimilar Competition on the US Market.
[5] Novartis. (2023). Cosentyx Product Monograph.
